Application Number [ ] SEARCH

IDS Flag Clearance for Application 09787426

IDS Information

Content	Mailroom Date	Entry Number	IDS Review	Reviewer
M844	10-22-2001	14	☑	11-09-2001 06:49:10 EXPO-CONV
M844	01-31-2006	51	☑	05-09-2006 18:00:18 DRao

UPDATE

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1763	((544/320,321) or (514/272)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/05/09 18:56

NPL

		Results
1.	TITLE-ABSTR-KEY(tpk or tau protein kinase) and TITLE-ABSTR-KEY(alzheimer) *[All Sources(- All Sciences -)]*	73

Rinsho Byori. The Japanese Journal Of Clinical Pathology
Volume 46, Issue 10 , October 1998, Pages 1003-1007
ISSN: 0047-1860

Involvement of tau protein kinase in amyloid-beta-induced neurodegeneration

Ishiguro, K

Mitsubishi Kasei Institute of Life Sciences, Machida

Abstract

Histopathological features of **Alzheimer's** disease (AD) include extracellular deposits of amyloid beta (A beta) fibrils in the cores of senile plaques, intracellular neurofibrillary tangles (NFT) which are composed of paired helical filaments (PHF), and neuronal cell loss. The main component of PHF is highly phosphorylated tau protein. We identified a protein kinase converting normal tau into a PHF-like state. The kinase is **tau protein kinase (TPK)** I/glycogen synthase kinase (GSK)-3 beta. Using a neuronal cell culture system as an AD model, it was recognized that **TPK** I/GSK-3 beta plays a central role in AD pathology. We hypothesize that A beta-induced neuronal cell death occurs by the following mechanism. A beta inactivates PI3-kinase and activates **TPK** I/GSK-3 beta, which in turn phosphorylates and inactivates both tau and pyruvate dehydrogenase (PDH). After the ability of tau to promote microtubule assembly is diminished by phosphorylation, soluble tau molecules aggregate into PHF by an unknown mechanism. Destabilization of microtubule arrays causes inhibition of axonal transport and accumulation of amyloid precursor protein (APP). Phosphorylation of PDH inhibits the reaction converting pyruvate to acetyl-CoA, resulting in inhibition of energy metabolism and a decrease in acetylcholine, both of which are also characteristics of AD. These changes may lead to neuronal cell death. [Journal Article, Review; 20 Refs; In Japanese; Japan; MEDLINE]

CAS Registry Numbers: Amyloid beta-Protein; EC 2.7.1.135, **tau-protein kinase;** EC 2.7.1.37, Protein-Serine-Threonine Kinases

Citation Subset Indicators: Index Medicus

MeSH Terms: ‹Alzheimer› Disease, * pathology (PA); Amyloid beta-Protein, * pharmacology (PD); Animals; Cell Death; English Abstract; * Nerve Degeneration; Protein-Serine-Threonine Kinases, * physiology (PH); Rats

---

Rinsho Byori. The Japanese Journal Of Clinical Pathology
Volume 46, Issue 10 , October 1998, Pages 1003-1007
ISSN: 0047-1860

Neurobiology Of Aging
Volume 19, Issue 1, Supplement , January - February 1998, Pages S93-S98
ISSN: 0197-4580

Possible role of tau protein kinases› in pathogenesis of ‹Alzheimer's› disease

Imahori, K; Hoshi, M; Ishiguro, K; Sato, K; Takahashi, M; Shiurba, R; Yamaguchi, H; Takashima, A; Uchida, T

Mitsubishi Kasei Institute of Life Sciences, Machida, Tokyo, Japan; e-mail scrtry@libra.ls.m-kagaku.co.jp

Abstract

‹**Tau protein kinases (TPK)**› I and II were isolated as candidate enzymes responsible for the hyperphosphorylation observed in PHF-tau. Four phosphorylation sites of tau were identified for each kinase, accounting for most, but not all, of the major phosphorylation sites of PHF-tau. Immunostaining with anti-TPKI antibody indicated that this kinase is up-regulated in AD brain. Such up-regulation of TPKI and phosphorylatioin of tau were reproduced by treating cultured hippocampal cells with amyloid beta (Abeta) protein. In addition, we found that TPKI can phosphorylate and inactivate pyruvate dehydrogenase (PDH), which is expected to result in depletion of acetyl-CoA, a key substrate of acetyl choline synthesis. Indeed, when septum cells were treated with Abeta, the level of acetyl choline decreased dramatically. [Journal Article, Review; 23 Refs; In English; United States; MEDLINE]

CAS Registry Numbers: EC 2.7.1.-, ‹**tau protein kinase**› II; EC 2.7.1.135, ‹**tau-protein kinase;**› EC 2.7.1.37, Protein-Serine-Threonine Kinases

Citation Subset Indicators: Index Medicus

MeSH Terms: ‹**Alzheimer**› Disease, * enzymology (EN), metabolism (ME), * pathology

(PA); Humans; Phosphorylation; Protein-Serine-Threonine Kinases, biosynthesis (BI), * metabolism (ME)

Neurobiology Of Aging
Volume 19, Issue 1, Supplement , January - February 1998, Pages S93-S98
ISSN: 0197-4580

C:\Program Files\Stnexp\Queries\09787426.str





chain nodes :
7 8 11 13
ring nodes :
1 2 3 4 5 6
ring/chain nodes :
14
chain bonds :
1-11 5-7 11-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-11 2-3 3-4 4-5 5-6 5-7 11-13 13-14
isolated ring systems :
containing 1 :

G1:C,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 10:CLASS 11:CLASS
13:CLASS 14:CLASS
Generic attributes :
8:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

Element Count :
Node 8: Limited
C,C5
N,N1

O,OO
S,S0

C:\Program Files\Stnexp\Queries\09787426 (sub).st





chain nodes :
7 10 11
ring nodes :
1 2 3 4 5 6
chain bonds :
4-10 5-7 10-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 10-11
exact bonds :
4-10
isolated ring systems :
containing 1 :

G1:C,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 10:CLASS 11:Atom

=>
Uploading C:\Program Files\Stnexp\Queries\09787426.str



chain nodes :
7 8 11 13
ring nodes :
1 2 3 4 5 6
ring/chain nodes :
14
chain bonds :
1-11 5-7 11-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-11 2-3 3-4 4-5 5-6 5-7 11-13 13-14
isolated ring systems :
containing 1 :

G1:C,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 10:CLASS 11:CLASS
13:CLASS 14:CLASS
Generic attributes :
8:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

Element Count :
Node 8: Limited
C,C5
N,N1
O,O0
S,S0

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 11:12:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     6815 TO ITERATE

 29.3% PROCESSED     2000 ITERATIONS                                 5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       131351 TO   141249
PROJECTED ANSWERS:              93 TO      587

L2             5 SEA SSS SAM L1

=> => s l1 sss ful
FULL SEARCH INITIATED 11:13:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   135798 TO ITERATE

100.0% PROCESSED   135798 ITERATIONS                             443 ANSWERS
SEARCH TIME: 00.00.05

L3           443 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\09787426 (sub).str
```






```
chain nodes :
7  10  11
ring nodes :
1  2  3  4  5  6
chain bonds :
4-10  5-7  10-11
```

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 10-11
exact bonds :
4-10
isolated ring systems :
containing 1 :

G1:C,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 10:CLASS 11:Atom

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



G1 C,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l4 sub=l3 sss sam
SAMPLE SUBSET SEARCH INITIATED 11:14:50 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED 20 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 132 TO 668
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 8 TO 329

L5 8 SEA SUB=L3 SSS SAM L4

=> => s l4 sub=l3 sss ful
FULL SUBSET SEARCH INITIATED 11:15:35 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 443 TO ITERATE

100.0% PROCESSED 443 ITERATIONS 218 ANSWERS
SEARCH TIME: 00.00.01

```
L6          218 SEA SUB=L3 SSS FUL L4

=> s l3 not l6
L7          225 L3 NOT L6

=> => s l7
L8           18 L7

=> d l8 1-18 bib,ab,hitstr
```

L8 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:902688 CAPLUS
DN 143:248403
TI Preparation of 2-aminopyrimidinones for inhibiting hYAK3 proteins
IN Hasegawa, Masaichi; Takada, Mio; Washio, Yoshiaki
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005076854	A2	20050825	WO 2005-US2972	20050203
WO 2005076854	A3	20051222		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-542090P P 20040204
OS MARPAT 143:248403
AB The title compds. I [R1 = quinolinyl, benzodioxolanyl, benzimidazolyl, etc.; R2 = pyridyl, benzimidazolyl, indazolyl, etc.], useful for inhibiting hYAK3 proteins, were prepared E.g., a multi-step synthesis of I [R1 = quinolin-6-yl; R2 = (CH2)2NH2], starting from 2,4,6-trichloropyrimidine and 6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)quinoline, was given. The compds. I were tested for their ability to inhibit the hYAK3 kinase (specific data were given for representative compds. I). The pharmaceutical composition comprising the compound I and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins by administering an ED of compound I were disclosed.
IT **263244-38-8P 263244-39-9P 863328-08-9P 863328-09-0P 863328-11-4P 863328-13-6P 863328-14-7P 863328-15-8P 863328-16-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-aminopyrimidinones for inhibiting hYAK3 proteins)
RN 263244-38-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(phenylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-39-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-methoxyphenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 863328-08-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-chlorophenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 863328-09-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(1H-indazol-6-ylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 863328-11-4 CAPLUS
CN Benzenesulfonamide, 3-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 863328-13-6 CAPLUS
CN Benzoic acid, 3-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 863328-14-7 CAPLUS
CN Benzenesulfonamide, 4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 863328-15-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 863328-16-9 CAPLUS
CN Acetamide, N-[3-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:78231 CAPLUS
DN 142:155972
TI A preparation of heterocyclic compounds, useful for the treatment of diseases associated with TNF-α, IL-1β, IL-6, and COX-1/COX-2
IN Dominguez, Celia; Harvey, Timothy Scot; Liu, Longbin; Siegmund, Aaron
PA Amgen Inc., USA
SO U.S. Pat. Appl. Publ., 28 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005020592	A1	20050127	US 2004-897884	20040723
AU 2004261587	A1	20050210	AU 2004-261587	20040723
CA 2533684	AA	20050210	CA 2004-2533684	20040723
WO 2005012286	A1	20050210	WO 2004-US23687	20040723

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-490312P P 20030725
WO 2004-US23687 W 20040723
OS MARPAT 142:155972
AB The invention relates to a preparation of heterocyclic compds. of formula I [wherein: Y is (un)saturated 5-7-membered ring containing 0-3 heteroatoms selected from N, O, or S; R1 is aryl or heterocyclic ring; R2 is substituted alkyl; R3 is NO2, NH(alkyl), or NHC(O)-alkyl, etc.; X, W, and V are independently selected from N, C(O), C(:S), or CH, etc.], useful for the treatment of diseases associated with TNF-α, IL-1β, IL-6, and COX-1/COX-2 (no biol. data). The invention compds. are useful for the treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, acute or chronic myelogenous leukemia, type I diabetes, type II diabetes, bone resorption diseases, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), and influenza, etc. For instance, pyrimidine derivative II was prepared via amination of 3-methyl-2-methylsulfanyl-5-nitro-6-(pyridin-4-yl)-3H-pyrimidin-4-one by (S)-3-phenylpropane-1,2-diamine and subsequent reduction of the nitro-group.
IT **831231-64-2P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic compds. useful for the treatment of disease associated with TNF-α, IL-1, IL-6, and COX-1/COX-2)
RN 831231-64-2 CAPLUS
CN Carbamic acid, [(1S)-1-[[[5-amino-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **831231-62-0P 831231-69-7P 831231-70-0P**
831231-71-1P 831231-72-2P 831231-73-3P
831231-74-4P 831231-78-8P 831232-00-9P
831232-02-1P 831232-03-2P 831232-05-4P
831232-06-5P 831232-07-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. useful for the treatment of disease associated with TNF-α, IL-1, IL-6, and COX-1/COX-2)

RN 831231-62-0 CAPLUS

CN 4(3H)-Pyrimidinone, 5-amino-2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831231-69-7 CAPLUS

CN Benzamide, N-[2-[[(2S)-2-amino-3-phenylpropyl]amino]-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831231-70-0 CAPLUS
CN Carbamic acid, [(1S)-1-[[[5-(acetylamino)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831231-71-1 CAPLUS
CN Carbamic acid, [(1S)-1-[[[1,6-dihydro-1-methyl-6-oxo-5-[(phenylsulfonyl)amino]-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831231-72-2 CAPLUS
CN Carbamic acid, [(1S)-1-[[[1,6-dihydro-1-methyl-6-oxo-5-[[(phenylamino)carbonyl]amino]-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831231-73-3 CAPLUS
CN Carbamic acid, [(1S)-1-[[[1,6-dihydro-1-methyl-5-[(methylsulfonyl)amino]-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831231-74-4 CAPLUS
CN Carbamic acid, [(1S)-1-[[[1,6-dihydro-1-methyl-6-oxo-5-[[(phenylmethoxy)carbonyl]amino]-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831231-78-8 CAPLUS
CN Carbamic acid, [(1S)-1-[[[1,6-dihydro-1-methyl-6-oxo-5-[(phenylmethyl)amino]-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831232-00-9 CAPLUS
CN Acetamide, N-[2-[[(2S)-2-amino-3-phenylpropyl]amino]-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831232-02-1 CAPLUS
CN Benzenesulfonamide, N-[2-[[(2S)-2-amino-3-phenylpropyl]amino]-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831232-03-2 CAPLUS
CN Carbamic acid, [2-[[(2S)-2-amino-3-phenylpropyl]amino]-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-5-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831232-05-4 CAPLUS
CN Urea, N-[2-[[(2S)-2-amino-3-phenylpropyl]amino]-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-5-pyrimidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831232-06-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-[(phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831232-07-6 CAPLUS
CN Methanesulfonamide, N-[2-[[(2S)-2-amino-3-phenylpropyl]amino]-1,6-dihydro-

1-methyl-6-oxo-4-(4-pyridinyl)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **831231-61-9P 831231-63-1P 831231-92-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. useful for the treatment of disease associated with TNF-α, IL-1, IL-6, and COX-1/COX-2)

RN 831231-61-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-nitro-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831231-63-1 CAPLUS

CN Carbamic acid, [(1S)-1-[[[1,6-dihydro-1-methyl-5-nitro-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831231-92-6 CAPLUS
CN Benzoic acid, 2-bromo-6-[[[2-[[(2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-phenylpropyl]amino]-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-5-pyrimidinyl]imino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L8 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:356440 CAPLUS
DN 138:368904
TI Preparation of 3-substituted 4-pyrimidones as tau protein kinase 1 inhibitors
IN Uehara, Fumiaki; Aritomo, Keiichi; Shoda, Aya; Hiki, Shinsuke; Okuyama, Masahiro; Usui, Yoshihiro; Ooizumi, Mitsuru; Watanabe, Kazutoshi; Yamakoshi, Koichi
PA Mitsubishi Pharma Corporation, Japan; Sanofi-Synthelabo
SO PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003037888	A1	20030508	WO 2002-JP9685	20020920
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2460121	AA	20030508	CA 2002-2460121	20020920
	EP 1427720	A1	20040616	EP 2002-772871	20020920
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002012892	A	20040803	BR 2002-12892	20020920
	CN 1556804	A	20041222	CN 2002-818469	20020920
	JP 2005510506	T2	20050421	JP 2003-540169	20020920
	US 2005090490	A1	20050428	US 2003-489606	20020920
	NZ 531636	A	20051125	NZ 2002-531636	20020920
	ZA 2004001845	A	20050307	ZA 2004-1845	20040305
	ZA 2004001850	A	20050307	ZA 2004-1850	20040305
	NO 2004001600	A	20040616	NO 2004-1600	20040420
PRAI	JP 2001-331674	A	20010921		
	JP 2001-331675	A	20010921		
	JP 2001-331677	A	20010921		
	JP 2001-331678	A	20010921		
	WO 2002-JP9685	W	20020920		

OS MARPAT 138:368904
AB The title compds. [I; R1 = (un)substituted alkyl; R = NHCR2R3COR4, II-IV (wherein R2, R3 = H, alkyl; R4 = (un)substituted Ph, naphthyl, indanyl, etc.; R5 = (un)substituted alkyl, cycloalkyl, Ph, etc.; R6 = H, (un)substituted alkyl, Ph; or R5 and R6 may bind to each other to form spiro carbocylic ring having 3-11 ring-constituting atoms in total; R7, R8 = H, alkyl; or R7 and R8 may combine to each other to form alkylene; R9 and R10 = (un)substituted alkyl, cycloalkyl, Ph, etc.; X = CH2, O, NR13; R13 = H, alkyl)], useful for preventive or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity (e.g. Alzheimer's disease), were prepared and formulated. Thus, reacting 2-amino-1-phenylethanone.HCl with 2-chloro-3-methyl-6-(4-pyridyl)pyrimidine-4-one (preparation given) in the presence of DMAP and Et3N in DMSO afforded 68% V which showed IC50 of 8.9 nM against P-GS1 phosphorylation by bovine

cerebral TPK1.

IT **521967-13-5P 521967-14-6P 521967-15-7P**
521967-16-8P 521967-17-9P 521967-18-0P
521967-19-1P 521969-49-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-substituted 4-pyrimidones as tau protein kinase 1 inhibitors)

RN 521967-13-5 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(2-oxo-2-phenylethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 521967-14-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2-fluorophenyl)-2-oxoethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 521967-15-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(3-fluorophenyl)-2-oxoethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 521967-16-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-fluorophenyl)-2-oxoethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 521967-17-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(3-chlorophenyl)-2-oxoethyl]amino]-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521967-18-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-bromophenyl)-2-oxoethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 521967-19-1 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[2-(3-methylphenyl)-2-oxoethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 521969-49-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(3-chlorophenyl)-2-oxoethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:201429 CAPLUS
DN 138:4569
TI Solid phase synthesis of structurally diverse tetra substituted pyrimidines for potential use in combinatorial chemistry
AU Chauhan, P. M. S.; Kumar, Arun
CS Medicinal Chemistry Division, Central Drug Research Institute, Lucknow, 226001, India
SO Combinatorial Chemistry and High Throughput Screening (2002), 5(1), 93-95
CODEN: CCHSFU; ISSN: 1386-2073
PB Bentham Science Publishers
DT Journal
LA English
OS CASREACT 138:4569
AB A new pyrimidine based scaffold has been identified for generation of combinatorial libraries using solid phase technique. The utility of the scaffolds was demonstrated by synthesizing small libraries of 12 substituted pyrimidines I (Ar = 4-ClC6H4, 3-BrC6H4, 2-HO-5-BrC6H3, 4-HOC6H4, etc.).
IT **476436-93-8P 476436-94-9P**
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(solid phase synthesis of a tetra-substituted pyrimidine library via cyclocondensation reaction of resin bound thiourea with Et cyanoacetate and arylaldehydes)
RN 476436-93-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(butylamino)-1,4-dihydro-4-oxo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 476436-94-9 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(butylamino)-1,4-dihydro-4-oxo-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:116972 CAPLUS
DN 137:125132
TI Syntheses of novel antimycobacterial combinatorial libraries of structurally diverse substituted pyrimidines by three-component solid-phase reactions
AU Kumar, Arun; Sinha, Sudhir; Chauhan, Prem M. S.
CS Medicinal Chemistry Division, Central Drug Research Institute, U.P., Lucknow, 226001, India
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(4), 667-669
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 137:125132
AB A new pyrimidine based scaffold has been developed by three-component solid-phase syntheses. The utility of scaffolds was demonstrated by synthesizing libraries of 80 substituted pyrimidines. Among 80 compds. screened, six compds. showed in vitro activity against Mycobacterium tuberculosis(MABA) at a concentration of 50 and 25 μg/mL.
IT **443970-98-7P 443970-99-8P 443971-00-4P**
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)
(preparation of antimycobacterial combinatorial libraries of pyrimidines by three-component solid-phase reactions)
RN 443970-98-7 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-2-(octylamino)-4-oxo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 443970-99-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-4-oxo-2-(propylamino)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 443971-00-4 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-2-[[2-(4-morpholinyl)ethyl]amino]-4-oxo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:713340 CAPLUS
DN 135:272981
TI Preparation of 2-(arylalkylamino)pyrimidones and 2-(heteroarylalkylamino)pyrimidones for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β
IN Almario Garcia, Antonio; Ando, Ryoichi; Aritomo, Keiichi; Frost, Jonathan Reid; Li, Adrien Tak; Shoda, Aya; Uehara, Fumiaki; Watanabe, Kazutoshi
PA Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001070727	A1	20010927	WO 2001-EP3638	20010322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1136484	A1	20010926	EP 2000-400804	20000323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EP 1136099	A1	20010926	EP 2000-400805	20000323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EP 1136491	A1	20010926	EP 2000-400806	20000323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001270884	A2	20011002	JP 2000-81938	20000323
	AU 2001048365	A5	20011003	AU 2001-48365	20010322
PRAI	EP 2000-400804	A	20000323		
	EP 2000-400805	A	20000323		
	EP 2000-400806	A	20000323		
	JP 2000-81938	A	20000323		
	WO 2001-EP3638	W	20010322		

OS MARPAT 135:272981
AB The title compds. [I; R2 = H, perhalogenated alkyl, (un)substituted alkyl; R3 = 2-, 3- or 4-pyridyl optionally substituted by alkyl, alkoxy or a halogen; and when n = 1-10, the R1 = unsubstituted naphth-1-yl, unsubstituted naphth-2-yl, aryl, etc.; when n = 4-10 then R1 can represent in addition an unsubstituted Ph; and when n = 1-3 and R1 = unsubstituted Ph then R2 = perhalogenated alkyl or substituted alkyl] and their pharmaceutically acceptable salts which are used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3β, were prepared and formulated. The compds. I were synthesized by reacting Et 3-(4-pyridyl)-3-oxopropionate (preparation given) with R1(CH2)nNR2C(:NH)NH2 or by reacting 2-(methylthio)-6-(pyridin-4-yl)pyrimidin-4(1H)-one (preparation given) with R1(CH2)nNHR2. The compds. I such as I [R1 = 3,4-(MeO)2C6H3; R2 = H; R3 = 4-pyridyl] showed IC50's of 0.01-10 μM against GSK3β.

IT **361484-66-4P 361484-67-5P 361484-68-6P**
361542-10-1P 361542-11-2P 361542-12-3P
361542-13-4P 361542-14-5P 361542-15-6P
361542-16-7P 361542-17-8P 361542-18-9P
361542-19-0P 361542-20-3P 361542-21-4P
361542-22-5P 361542-23-6P 361542-24-7P
361542-25-8P 361542-26-9P 361542-27-0P
361542-28-1P 361542-29-2P 361542-30-5P
361542-31-6P 361542-32-7P 361542-33-8P
361542-34-9P 361542-35-0P 361542-36-1P
361542-37-2P 361542-38-3P 361542-39-4P
361542-40-7P 361542-41-8P 361542-42-9P
361542-43-0P 361542-44-1P 361542-45-2P
361542-46-3P 361542-47-4P 361542-48-5P
361542-49-6P 361542-50-9P 361542-51-0P
361542-52-1P 361542-54-3P 361542-55-4P
361542-56-5P 361542-57-6P 361542-58-7P
361542-59-8P 361542-60-1P 361542-61-2P
361542-62-3P 361542-63-4P 361542-64-5P
361542-65-6P 361542-66-7P 361542-67-8P
361542-68-9P 361542-69-0P 361542-70-3P
361542-71-4P 361542-72-5P 361542-73-6P
361542-75-8P 361542-76-9P 361542-77-0P
361542-78-1P 361542-79-2P 361542-80-5P
361542-82-7P 361542-84-9P 361542-85-0P
361542-86-1P 361542-87-2P 361542-89-4P
362048-04-2P 362048-06-4P 362048-07-5P
362048-08-6P 362048-09-7P 362048-10-0P
362048-12-2P 362048-13-3P 362048-14-4P
362601-30-7P 362601-35-2P 362601-36-3P
362601-37-4P 362601-38-5P 362601-39-6P
362601-41-0P 362601-42-1P 362601-43-2P
362601-44-3P 362601-45-4P 362601-47-6P
362601-49-8P 362601-50-1P 362601-51-2P
362601-52-3P 362601-54-5P 362601-55-6P
362601-56-7P 362601-58-9P 362601-59-0P
362601-60-3P 362601-61-4P 362601-62-5P
362601-64-7P 362601-65-8P 362601-67-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(arylalkylamino)pyrimidones and 2-(heteroarylalkylamino)pyrimidones for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β)

RN 361484-66-4 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(3-furanylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361484-67-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(1H-imidazol-1-yl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361484-68-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(2-thienyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-10-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-11-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-12-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-13-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-14-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-15-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-16-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-17-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-18-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-bromophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-19-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2,4-dichlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-20-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-21-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-22-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-nitrophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-23-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-aminophenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-24-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-25-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-26-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-27-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-methylphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-28-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 361542-29-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-30-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-phenylbutyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-31-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-[1,1'-biphenyl]-4-ylethyl)amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-32-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-naphthalenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-33-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-6-(4-
pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 361542-34-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(4-
pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 361542-35-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-methylphenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-36-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-37-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-fluorophenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-38-3 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[(2-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-39-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-40-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]
amino]- (9CI) (CA INDEX NAME)



RN 361542-41-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-
pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-42-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-nitrophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-43-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-aminophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-44-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-methylphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-45-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-methylphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-46-3 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[(2-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-47-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-48-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-49-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-aminophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-50-9 CAPLUS
CN Acetamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-
pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-51-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-52-1 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(2-pyridinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-54-3 CAPLUS
CN Carbamic acid, [[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361542-55-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-aminophenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-56-5 CAPLUS
CN Benzamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-57-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-58-7 CAPLUS
CN Methanesulfonamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-59-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[(2-pyrimidinylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-60-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-[(butylamino)methyl]phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 361542-61-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-62-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(4-aminobutoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-63-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-methylphenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-64-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-methylphenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-65-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-methylphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-66-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-67-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-68-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-69-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-70-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-71-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-72-5 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[3-(4-pyridinyl)propoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-73-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(3-pyridinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-75-8 CAPLUS
CN Carbamic acid, [[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]methylamino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361542-76-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]methylamino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-77-0 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[3-(3,4-dimethoxyphenyl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-78-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-[1,1'-biphenyl]-4-ylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-79-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-80-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-82-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-84-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-85-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-[(butylamino)methyl]phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-86-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-87-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(4-aminobutoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-89-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-04-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-06-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(5-methoxy-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-07-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(5-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-08-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-09-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-methoxy-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-10-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-fluoro-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-12-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-13-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-14-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-30-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(3-pyridinylmethoxy)phenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-35-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(2-pyridinylmethoxy)phenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-36-3 CAPLUS
CN Acetamide, N-[4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl](2-phenylethyl)amino]butyl]- (9CI) (CA INDEX NAME)



RN 362601-37-4 CAPLUS
CN Methanesulfonamide, N-[4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl](2-phenylethyl)amino]butyl]- (9CI) (CA INDEX NAME)



RN 362601-38-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methoxyphenyl)ethyl](phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-39-6 CAPLUS
CN Carbamic acid, [4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl](2-phenylethyl)amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 362601-41-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-aminobutyl)(2-phenylethyl)amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-42-1 CAPLUS
CN Carbamic acid, [4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl][2-(2-methoxyphenyl)ethyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 362601-43-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-aminobutyl)[2-(2-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-44-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-aminobutyl)(3-phenylpropyl)amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-45-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-naphthalenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 362601-47-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[2-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-49-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[2-[3-(4-pyridinyl)propoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 362601-50-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-phenylpropyl)(trifluoromethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-51-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 362048-04-2
CMF C19 H17 N5 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 362601-52-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-54-5 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 362601-55-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 362601-56-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 362601-58-9 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 362601-59-0 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(4-pyridinyl)ethyl]amino]- (9CI)

(CA INDEX NAME)



RN 362601-60-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[methyl[2-(2-pyridinyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-61-4 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[3-(3-pyridinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 362601-62-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(phenylmethyl)[2-(2-pyridinyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-64-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-phenylethyl)(3-pyridinylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-65-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-phenylethyl)(2-pyridinylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-67-0 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:709747 CAPLUS
DN 135:257262
TI Preparation of 2-[(heteroaryl)alkylamino]pyrimidones as GSK3β inhibitors
IN Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak
PA Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1136491	A1	20010926	EP 2000-400806	20000323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	WO 2001070727	A1	20010927	WO 2001-EP3638	20010322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001048365	A5	20011003	AU 2001-48365	20010322
PRAI	EP 2000-400804	A	20000323		
	EP 2000-400805	A	20000323		
	EP 2000-400806	A	20000323		
	JP 2000-81938	A	20000323		
	WO 2001-EP3638	W	20010322		

OS MARPAT 135:257262
AB The title compds. [I; R1 = H, alkyl; R2 = (un)substituted furyl, thienyl, pyrrolyl or imidazolyl; R3 = 2-, 3- or 4-pyridyl optionally substituted by alkyl, alkoxy or halogen; n = 1-5] which are used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents, brain and spinal trauma, and peripheral neuropathies, were prepared and formulated. Thus, reacting 2-(methylthio)-6-(pyridin-4-yl)pyrimidin-4(1H)-one (preparation given) with 3-furylmethylamine afforded I [R1 = H; R2 = 3-furyl; R3 = 4-pyridyl; n = 1]. The exemplified compds. I showed IC50's of 0.3-10 μM against GSK3β.
IT **361484-66-4P 361484-67-5P 361484-68-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-[(heteroaryl)alkylamino]pyrimidones as GSK3β inhibitors)
RN 361484-66-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-furanylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361484-67-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(1H-imidazol-1-yl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361484-68-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(2-thienyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:709744 CAPLUS
DN 135:257260
TI Preparation of 2-[(indanylamino]pyrimidones and 2-[tetrahydronaphthalenylamino]pyrimidones as GSK3β inhibitors
IN Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak
PA Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1136486	A1	20010926	EP 2000-400808	20000323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	WO 2001070725	A1	20010927	WO 2001-EP3636	20010322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001062149	A5	20011003	AU 2001-62149	20010322
PRAI	EP 2000-400808	A	20000323		
	WO 2001-EP3636	W	20010322		

OS MARPAT 135:257260
AB The title compds. [I; R1 = H, alkyl; R2 = H, alkyl, halo, etc.; R3 = 2-, 3- or 4-pyridyl group optionally substituted by alkyl, alkoxy or a halogen atom; n = 0-1; when n = 0 then m = 2 or 3, and when n = 1 then m = 1 or 2] which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents and brain and spinal trauma and peripheral neuropathies, were prepared and formulated. E.g., a 3-step synthesis of I [R1, R2 = H; R3 = 4-pyridyl; n, m = 1] which showed IC50 of 0.1 μM against GSK3β, was given.
IT **361458-95-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-[(indanylamino]pyrimidones and 2-[tetrahydronaphthalenylamino]pyrimidones as GSK3β inhibitors)
RN 361458-95-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2,3-dihydro-1H-inden-2-yl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:709742 CAPLUS
DN 135:257258
TI Preparation of 2-(arylalkylamino)pyrimidones as GSK3β inhibitors
IN Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak; Ando, Ryoichi; Watanabe, Kazutoshi
PA Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SO Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1136484	A1	20010926	EP 2000-400804	20000323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	WO 2001070727	A1	20010927	WO 2001-EP3638	20010322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001048365	A5	20011003	AU 2001-48365	20010322
PRAI	EP 2000-400804	A	20000323		
	EP 2000-400805	A	20000323		
	EP 2000-400806	A	20000323		
	JP 2000-81938	A	20000323		
	WO 2001-EP3638	W	20010322		

OS MARPAT 135:257258
AB The title compds. [I; R1 = unsubstituted naphth-1-yl, unsubstituted naphth-2-yl, substituted aryl; when n = 4-5 then R1 can represent unsubstituted Ph; R2 = H, alkyl; R3 = 2-, 3- or 4-pyridyl optionally substituted by alkyl, alkoxy group or a halogen atom] which are used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, were prepared and formulated. The compds. I were prepared by reacting the propionate R3COCH2COOR with the amidine R1(CH2)nNR2C(:NH)NH2 or by reacting the pyrimidinone II with amine R1(CH2)nNHR2. All exemplified compds. I such as I [R1 = 3,4-(MeO)2C6H3; R2 = H; R3 = 4-pyridyl; n = 1] showed IC50 of 0.01-10 μM against GSK3β.
IT **361542-10-1P 361542-11-2P 361542-12-3P**
361542-13-4P 361542-14-5P 361542-15-6P
361542-16-7P 361542-17-8P 361542-18-9P
361542-19-0P 361542-20-3P 361542-21-4P
361542-22-5P 361542-23-6P 361542-24-7P
361542-25-8P 361542-26-9P 361542-27-0P
361542-28-1P 361542-29-2P 361542-30-5P
361542-31-6P 361542-32-7P 361542-33-8P
361542-34-9P 361542-35-0P 361542-36-1P
361542-37-2P 361542-38-3P 361542-39-4P
361542-40-7P 361542-41-8P 361542-42-9P
361542-43-0P 361542-44-1P 361542-45-2P
361542-46-3P 361542-47-4P 361542-48-5P

361542-49-6P 361542-50-9P 361542-51-0P
361542-52-1P 361542-53-2P 361542-54-3P
361542-55-4P 361542-56-5P 361542-57-6P
361542-58-7P 361542-59-8P 361542-60-1P
361542-61-2P 361542-62-3P 361542-63-4P
361542-64-5P 361542-65-6P 361542-66-7P
361542-67-8P 361542-68-9P 361542-69-0P
361542-70-3P 361542-71-4P 361542-72-5P
361542-73-6P 361542-74-7P 361542-75-8P
361542-76-9P 361542-77-0P 361542-78-1P
361542-79-2P 361542-80-5P 361542-81-6P
361542-82-7P 361542-83-8P 361542-84-9P
361542-85-0P 361542-86-1P 361542-87-2P
361542-88-3P 361542-89-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(arylalkylamino)pyrimidones as GSK3β inhibitors)

RN 361542-10-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-11-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-12-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-13-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-14-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-15-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-16-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-17-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-18-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-bromophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-19-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2,4-dichlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-20-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-21-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-22-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-nitrophenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-23-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-aminophenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-24-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-25-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-26-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-27-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-methylphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-28-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 361542-29-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-30-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-phenylbutyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-31-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-[1,1'-biphenyl]-4-ylethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-32-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-naphthalenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-33-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-34-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-35-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-methylphenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-36-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-37-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-fluorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-38-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-39-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-40-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-41-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-42-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-nitrophenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-43-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-aminophenyl)methyl]amino]-6-(4-pyridinyl)-

(9CI) (CA INDEX NAME)



RN 361542-44-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-methylphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-45-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-methylphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-46-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-47-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-48-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-chlorophenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-49-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-aminophenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-50-9 CAPLUS
CN Acetamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-51-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-52-1 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(2-pyridinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-53-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[3-(3-pyridinyl)propoxy]phenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-54-3 CAPLUS
CN Carbamic acid, [[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361542-55-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-aminophenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-56-5 CAPLUS
CN Benzamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-57-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-58-7 CAPLUS
CN Methanesulfonamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-

pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-59-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[(2-pyrimidinylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-60-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-[(butylamino)methyl]phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-61-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-62-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(4-aminobutoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-63-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-methylphenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-64-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-methylphenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-65-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-methylphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-66-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-67-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-68-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-69-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-70-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-71-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-72-5 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[3-(4-pyridinyl)propoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-73-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(3-pyridinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-74-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[2-(2-pyridinyl)ethoxy]phenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-75-8 CAPLUS
CN Carbamic acid, [[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]methylamino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361542-76-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]methylamino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-77-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3,4-dimethoxyphenyl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-78-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-[1,1'-biphenyl]-4-ylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-79-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-80-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-81-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-82-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-83-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[3-(3-pyridinyl)propoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-84-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-85-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-[(butylamino)methyl]phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-86-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-87-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(4-aminobutoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-88-3 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[2-(2-pyridinyl)ethoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-89-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:709740 CAPLUS
DN 135:257256
TI Preparation of 2-amino-3-alkyl-pyrimidones as GSK3β inhibitors
IN Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak; Ando, Ryoichi; Watanabe, Kazutoshi
PA Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1136482	A1	20010926	EP 2000-400800	20000323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2401241	AA	20010927	CA 2001-2401241	20010322
	WO 2001070729	A1	20010927	WO 2001-EP3640	20010322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001081487	A5	20011003	AU 2001-81487	20010322
	EP 1276738	A1	20030122	EP 2001-959921	20010322
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003528095	T2	20030924	JP 2001-568932	20010322
	US 2003187004	A1	20031002	US 2002-221598	20021202
	US 6844335	B2	20050118	← ODP (Homolog).	
	US 2005130998	A1	20050616	US 2005-35264	20050113
PRAI	EP 2000-400800	A	20000323		
	WO 2001-EP3640	W	20010322		
	US 2002-221598	A3	20021202		

OS MARPAT 135:257256
AB The title compds. [I; R1 = H, alkyl; R2 = (un)substituted alkyl, alkenyl, aryl, etc.; or R1 and R2 form together (un)substituted alkylene; or R1 and R2 form together (CH2)2X(CH2)2, (CH2)2X(CH2)3 (wherein X = O, S (un)substituted NH); R3 = 2-, 3- or 4-pyridyl group optionally substituted by alkyl alkoxy or halogen atom; R4 = alkyl optionally substituted by aryl], useful for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents, brain and spinal trauma, and peripheral neuropathies, were prepared and formulated. The compds. I synthesized by reacting 3-methyl-2-(methylthio)-6-pyridin-4-ylpyrimidin-4(3H)-one (preparation given) with the corresponding amine or by N-alkylation of the substituted 2-amino-3-methylpyrimidinone with alkyl iodide. The compds. I showed IC50's of 0.1-10 μM against GSK3β.
IT **362013-60-3P 362013-61-4P 362013-62-5P**
362013-63-6P 362013-64-7P 362013-65-8P
362013-66-9P 362013-67-0P 362013-68-1P

362013-69-2P 362013-70-5P 362013-71-6P
362013-72-7P 362013-73-8P 362013-74-9P
362013-75-0P 362013-76-1P 362013-77-2P
362013-78-3P 362013-79-4P 362013-80-7P
362013-81-8P 362013-82-9P 362013-83-0P
362013-84-1P 362013-85-2P 362013-86-3P
362013-87-4P 362013-88-5P 362013-89-6P
362013-90-9P 362013-91-0P 362013-92-1P
362013-93-2P 362013-94-3P 362013-95-4P
362013-96-5P 362013-97-6P 362013-98-7P
362014-02-6P 362014-03-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-amino-3-alkyl-pyrimidones as GSK3β inhibitors)

RN 362013-60-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(2-phenylethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-61-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-methoxyphenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-62-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(3-methoxyphenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-63-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2-methoxyphenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-64-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-65-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(3-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-66-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-67-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-bromophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-68-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-69-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2,4-dichlorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-70-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-aminophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-71-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-72-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-73-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-chlorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-74-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-75-0 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[2-(4-methylphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-76-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 362013-77-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(3-chlorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-78-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[[2-(2-thienyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 362013-79-4 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(4-phenylbutyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-80-7 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[2-[4-(phenylmethoxy)phenyl]ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-81-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(2-[1,1'-biphenyl]-4-ylethyl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-82-9 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-83-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2-methoxyphenyl)methyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-84-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2,5-dimethoxyphenyl)ethyl]methylamino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-85-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 362013-86-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 362013-87-4 CAPLUS
CN 4(3H)-Pyrimidinone, 3-(phenylmethyl)-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-88-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-89-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-3-methyl-6-(4-pyridinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 362013-88-5
CMF C20 H19 N5 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 362013-90-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(5-methoxy-1H-indol-3-yl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-91-0 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-92-1 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[2-(7-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-93-2 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-94-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[methyl[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-95-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(cyclopentylamino)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-96-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(ethylamino)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-97-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(ethylamino)-3-methyl-6-(4-pyridinyl)-, ethanedioate

(9CI) (CA INDEX NAME)

CM 1

CRN 362013-96-5
CMF C12 H14 N4 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 362013-98-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(2,3-dihydro-1H-inden-2-yl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362014-02-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362014-03-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:709694 CAPLUS
DN 135:262238
TI Preparation of 2-(indolylalkylamino)pyrimidone derivatives as gsk3beta inhibitors
IN Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak
PA Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SO Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1136099	A1	20010926	EP 2000-400805	20000323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	WO 2001070727	A1	20010927	WO 2001-EP3638	20010322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001048365	A5	20011003	AU 2001-48365	20010322
PRAI	EP 2000-400804	A	20000323		
	EP 2000-400805	A	20000323		
	EP 2000-400806	A	20000323		
	JP 2000-81938	A	20000323		
	WO 2001-EP3638	W	20010322		

OS MARPAT 135:262238
AB A pyrimidone derivative represented by formula I or a salt thereof: wherein: R1 represents a hydrogen atom or a C1-6 alkyl group; R2 represents a hydrogen atom or a C1-6 alkyl group; R3 represents a 2, 3 or 4-pyridyl group optionally substituted by a C1-4 alkyl group, a C1-4 alkoxy group or a halogen atom; R4 represents a hydrogen atom, a C1-6 alkyl group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group, methylenedioxy group, a nitro, a cyano, an amino, a C1-6 monoalkylamino group, C2-12 dialkylamino group, a C1-6 alkylcarbonylamino group, C6-10 arylcarbonylamino group, a Ph group or a benzyloxy group; and n represents 1 to 5. And a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β (as glycogen synthase kinase 3β)such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents, brain and spinal cord trauma and peripheral neuropathies. A solution of 2-(methylthio)-6-pyridinyl-4-ylpyrimidin-4(1H)-one and different indolylalkylamines in amyl alc. were heated at 150° for 72 h to obtain 2-[indolylalkylamino]-6-pyridin-4-ylpyrimidin-4(1H)-one derivs. Inhibitory activity of the above derivs. against gsk3β was tested. A tablet contained a 2-(indolylalkylamino)pyrimidone derivative 30, crystalline cellulose 60, corn starch 100, lactose 200, and magnesium stearate 4 mg.

IT **362048-05-3P 362048-06-4P 362048-07-5P**
362048-08-6P 362048-09-7P 362048-10-0P
362048-11-1P 362048-12-2P 362048-13-3P
362048-14-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolylalkylaminopyrimidone derivs. as glycogen synthase kinase inhibitors)

RN 362048-05-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 362048-04-2
CMF C19 H17 N5 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 362048-06-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(5-methoxy-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-07-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(5-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-

pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-08-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-09-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-methoxy-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-10-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-fluoro-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-11-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(7-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-12-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-13-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-14-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:227649 CAPLUS
DN 132:265206
TI Preparation of pyrimidones for treating diseases caused by tau protein kinase 1 hyperactivity such as Alzheimer disease
IN Watanabe, Kazutoshi; Ando, Ryoichi; Saito, Ken-ichi; Kawamoto, Rie; Shoda, Aya
PA Mitsubishi Chemical Corporation, Japan
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018758	A1	20000406	WO 1999-JP5224	19990924
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2345065	AA	20000406	CA 1999-2345065	19990924
	AU 9957599	A1	20000417	AU 1999-57599	19990924
	EP 1115721	A1	20010718	EP 1999-944815	19990924
	EP 1115721	B1	20031210		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002525366	T2	20020813	JP 2000-572218	19990924
	AT 256123	E	20031215	AT 1999-944815	19990924
	PT 1115721	T	20040430	PT 1999-944815	19990924
	ES 2214045	T3	20040901	ES 1999-944815	19990924
PRAI	JP 1998-271277	A	19980925		
	JP 1998-305266	A	19981027		
	WO 1999-JP5224	W	19990924		

OS MARPAT 132:265206
AB The title compds. [I; R1 = C1-18 alkyl, C3-18 alkenyl, C3-18 alkenyl, etc.; R2 = H, OH, C1-18 alkyl, etc.; R3 = (un)substituted pyridyl], useful for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as Alzheimer disease, were prepared and formulated. Thus, reacting Et 3-(4-pyridyl)-3-oxopropionate with 3-amidinopyridine.HCl in the presence of K2CO3 in EtOH afforded I [R1 = 3-pyridyl; R2 = H; R3 = 4-pyridyl] which showed IC50 of 2.3 μM against P-GS1 phosphorylation by bovine cerebral TPK1.
IT **54950-14-0P 54950-15-1P 263244-10-6P**
263244-16-2P 263244-25-3P 263244-26-4P
263244-27-5P 263244-30-0P 263244-31-1P
263244-32-2P 263244-34-4P 263244-35-5P
263244-36-6P 263244-37-7P 263244-38-8P
263244-39-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidones for treating diseases caused by tau protein kinase 1 hyperactivity such as Alzheimer disease)

RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-15-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-10-6 CAPLUS
CN Benzamide, N-[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 263244-16-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(diethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-25-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[methyl(phenylmethyl)amino]-6-(4-pyridinyl)- (9CI)

(CA INDEX NAME)



RN 263244-26-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-27-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3,3-diphenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-30-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[methyl(2-methylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-31-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dipropylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-32-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-hydroxypropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-34-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(cyclohexylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-35-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-ethylphenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-36-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-butoxyphenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-37-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-bromophenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-38-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(phenylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-39-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-methoxyphenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:59167 CAPLUS
DN 116:59167
TI Chemotherapeutic agents. XXI. Synthesis of π-deficient pyrimidines as leishmanicides
AU Ram, Vishnu J.
CS Med. Chem. Div., Cent. Drug Res. Inst., Lucknow, India
SO Archiv der Pharmazie (Weinheim, Germany) (1991), 324(11), 837-9
CODEN: ARPMAS; ISSN: 0365-6233
DT Journal
LA English
AB 5-Cyano-6-(3-pyridyl)-2-thiouracil (I) was prepared from 3-pyridinecarboxaldehyde, thiourea, and Et cyanoacetate. Alkylation of I with mono- and dihaloalkanes under different conditions, gave alkylated derivs. e.g. II (R = MeS, PhCH2S) and III. Halogenation of II (R = PhCH2S) with POCl3 followed by nucleophilic substitution with amines gave the corresponding amines, e.g. IV. Fusion of II (R = MeS) with aromatic and heterocyclic amines at 160° gave the substitution products e.g. II (R = 4-methylpiperazino). Some of the compds. were screened for antileishmanial activity but only one of them IV demonstrated very significant activity.
IT **138429-65-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 138429-65-9 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[(4-chlorophenyl)amino]-1,4-dihydro-4-oxo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:610998 CAPLUS
DN 101:210998
TI Dihydropyridinedicarboxylates
PA Pfizer Corp., USA
SO Jpn. Kokai Tokkyo Koho, 42 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 59118782	A2	19840709	JP 1983-241806	19831221
	JP 02025913	B4	19900606		
	US 4572908	A	19860225	US 1983-562482	19831216
	PL 140069	B1	19870331	PL 1983-245158	19831216
	PL 140573	B1	19870530	PL 1983-250215	19831216
	NO 8304689	A	19840622	NO 1983-4689	19831219
	NO 159272	B	19880905		
	NO 159272	C	19881214		
	EP 116769	A1	19840829	EP 1983-307719	19831219
	EP 116769	B1	19870325		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	ES 528157	A1	19850801	ES 1983-528157	19831219
	ZA 8309381	A	19850828	ZA 1983-9381	19831219
	EP 168841	A2	19860122	EP 1985-109347	19831219
	EP 168841	A3	19860219		
	EP 168841	B1	19880928		
	R: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 26114	E	19870415	AT 1983-307719	19831219
	IL 70477	A1	19870831	IL 1983-70477	19831219
	FI 8304692	A	19840622	FI 1983-4692	19831220
	FI 79104	B	19890731		
	FI 79104	C	19891110		
	AU 8322559	A1	19840628	AU 1983-22559	19831220
	AU 546057	B2	19850815		
	DK 8305865	A	19840727	DK 1983-5865	19831220
	DD 213920	A5	19840926	DD 1983-258248	19831220
	HU 32816	O	19840928	HU 1983-4351	19831220
	HU 193275	B	19870928		
	CA 1215050	A1	19861209	CA 1983-443770	19831220
	SU 1296006	A3	19870307	SU 1983-3682597	19831220
	CS 249516	B2	19870312	CS 1983-9668	19831220
	SU 1391499	A3	19880423	SU 1984-3739756	19840508
	ES 534723	A1	19850616	ES 1984-534723	19840730
	CS 249525	B2	19870312	CS 1984-7453	19841001
	US 4661485	A	19870428	US 1986-830292	19860214
	US 4670449	A	19870602	US 1986-830384	19860214
PRAI	GB 1982-36347	A	19821221		
	US 1983-562482	A3	19831216		
	EP 1983-307719	P	19831219		
	CS 1983-9668	A3	19831220		

OS CASREACT 101:210998; MARPAT 101:210998
AB Title compds. I [R = (un)substituted aryl, heteroaryl; R1, R2 = alkyl, MeOCH2CH2; R3 = (un)substituted heterocyclyl; Z = alkylene), useful as antihypertensives (data given on Ca++ transport inhibition), were prepared Thus, treating amine II (R4 = H) with (MeS)2C:NCN gave II (R4 = MeSC:NCN) which was treated with N2H4 to give I (R = 2-ClC6H4, R1 = Me, R2 = Et, R3

= 2-amino-1H-1,2,4-triazol-5-yl, Z = CH2CH2).

IT **93118-63-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antihypertensive activity of)

RN 93118-63-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-2-[[2-[[1,4-dihydro-4-oxo-6-(2-pyridinyl)-2-pyrimidinyl]amino]ethoxy]methyl]-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1976:44112 CAPLUS
DN 84:44112
TI 4-Hydroxy-pyridylpyrimidine derivatives
IN Tani, Hidero; Nakamura, Koji; Mori, Yasuhiro; Yokoo, Nobuo; Kyotani, Yoshinori; Wada, Yasushi
PA Kowa Co., Ltd., Japan
SO Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 49035631	B4	19740925	JP 1970-127611	19701228
PRAI JP 1970-127611		19701228		

AB Seven pyrimidinols (I, R = 2-, 3-, 4-pyridyl, R1 = H, Me, or R12N = morpholino), useful as antiinflammatory agents (no data), were prepared from the corresponding pyridylcarbonylacetic acid ester and guanidine derivs. [R12NC(:NH)NH2]. E.g., 54.9 g nicotinoylacetic acid Me ester in 53 g EtOAc was refluxed with EtO Na (obtained from 11.5 g Na and 200 ml EtOH) for 10 hr and the reaction mixture was adjusted with H2SO4 to pH 7 to give 24.95 g nicotinoylacetic acid Et ester, which (18.1 g) was refluxed 5 hr with 12.6 g H2NC(:NH)NH2 carbonate in 60 ml EtOH to give I (R = 3-pyridyl, R1 = H).

IT **54950-14-0P 54950-15-1P 54950-16-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-15-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-16-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(2-pyridinyl)- (9CI) (CA INDEX

NAME)



L8 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:410129 CAPLUS
DN 83:10129
TI 2-(Substituted)-4-hydroxy-6-pyridylpyrimidine derivatives
IN Tani, Hidero; Nakamura, Koji; Mori, Yasuhiro; Yokoo, Nobuo; Kyotani, Yoshinori; Wada, Yasushi
PA Mori, Hiroshi
SO Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DT Patent
LA Japanese

Same as #15

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 49035634	B4	19740925	JP 1970-128203	19701230
PRAI	JP 1970-128203		19701230		

AB Seven 2-amino-6-pyridyl-4-pyrimidinols (I, R = H2, Me, or R2N = morpholino; R1 = 2-, 3-, or 4-pyridyl), useful as antiinflammatory agents, were prepared from the 2-(methylthio) derivs. and the appropriate amines. E.g., 3.0 g 2-(methylthio)-6-(4-pyridyl)-4-pyrimidinol, obtained from reaction of H2NC(:S)NH2 with Et isonicotinoylacetate and subsequent methylation, was treated with 260 mg Me2NH in BuOH at 150° for 2 hr to give 76.5% I (R = Me, R1 = 4-pyridyl).

IT **54950-14-0P 54950-15-1P 54950-16-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-15-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-16-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:410127 CAPLUS
DN 83:10127
TI 5-Nitro-6-pyridylprimidine derivatives
IN Tani, Hidero; Nakamura, Koji; Yokoo, Nobuo; Kyotani, Yoshinori; Akaishi, Keisuke
PA Mori, Hiroshi
SO Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DT Patent
LA Japanese

Same as #15

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 49035633	B4	19740925	JP 1970-128199	19701230
PRAI JP 1970-128199		19701230		

AB Three 5-nitro-2-amino-4-(4-pyridyl)pyrimidines (R = H, Me; R1 = OH, NH2), useful as antiinflammatory agents, were prepared by nitration of the corresponding II. Thus, 15 g II (R = Me, R1 = NH2) was treated with a mixture of 10 ml fuming HNO3 and 50 ml H2SO4 for 1 hr and the mixture was treated with 28% NH3-H2O to give 8.08 g I (R = Me, R1 = NH2).

IT **54950-14-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(nitration of)
RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT **55361-89-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55361-89-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-5-nitro-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:171028 CAPLUS
DN 82:171028
TI 2,4,5-Trisubstituted-6-pyridylpyrimidine derivatives
IN Tani, Hideo; Nakamura, Koji; Yokoo, Nobuo; Kyoya, Yoshinori; Akashi, Keisuke
PA Mori, Hiroshi
SO Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DT Patent
LA Japanese

Same as #15.

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 49036719	B4	19741002	JP 1970-128201	19701230
PRAI JP 1970-128201		19701230		

AB Pyridylpyrimidinols [I, R = 1-piperidinylmethyl (II), morpholinomethyl], useful as antiinflammatory agents (no data), were prepared by reacting I (R = H) with RH and formalin. E.g., 650 mg I (R = H) was refluxed with 0.036 ml HOAc, 306 mg piperidine, 0.375 ml formalin and 6 ml EtOH for 45 min, the mixture allowed to stand for 2.5 hr, 0.1 ml formalin added, and the mixture again refluxed for 1.5 hr to give 44 mg II. II·HCl was also prepared

IT **54950-14-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with amines and formaldehyde)

RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



```
=> => d his

     (FILE 'HOME' ENTERED AT 11:11:31 ON 09 MAY 2006)

     FILE 'REGISTRY' ENTERED AT 11:11:35 ON 09 MAY 2006
L1              STRUCTURE UPLOADED
L2            5 S L1 SSS SAM
L3          443 S L1 SSS FUL
L4              STRUCTURE UPLOADED
L5            8 S L4 SSS SAM SUB=L3
L6          218 S L4 SSS FUL SUB=L3
L7          225 S L3 NOT L6

     FILE 'CAPLUS' ENTERED AT 11:15:48 ON 09 MAY 2006
L8           18 S L7

     FILE 'CAOLD' ENTERED AT 11:16:28 ON 09 MAY 2006

=> s l7
L9            0 L7

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.44     302.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00     -13.50

STN INTERNATIONAL LOGOFF AT 11:16:41 ON 09 MAY 2006
```